Oprah's Weight Loss Dilemma: The Ozempic

In the past week, discussions around Ozempic and weight loss drugs have intensified, blending policy debates with celebrity health rumors. Minnesota lawmakers grappled with costs in the House Health Finance and Policy Committee, where a bill, HF4142, sponsored by Representative something, aimed to prohibit Medical Assistance coverage for prescription drugs used solely for weight loss like Ozempic. The measure was laid over, sparking questions on whether funding these medications saves money long-term by preventing obesity-related illnesses. According to the Minnesota House Session Daily report from late March 2026, supporters argued that covering such drugs now could reduce future expenses for comorbidities stemming from obesity.

Oprah Winfrey remains at the center of Ozempic-related chatter, with fresh rumors about so-called Ozempic feet resurfacing after her appearances at Paris Fashion Week earlier this month. Nicki Swift reports that videos from the event showed Winfrey walking with slow, short steps, prompting online speculation that the GLP-1 drug, which she has used for weight management, weakened her muscles and caused sagging, veiny skin on her feet. Observers on X noted her frail gait at Stella McCartneys fashion show, dubbing it an Ozempic-induced shuffle similar to what others experience. Winfrey has not confirmed using Ozempic specifically but has praised GLP-1 medications openly. In past statements recalled amid this buzz, she described realizing thin people do not rely solely on willpower, as the drugs curb constant food thoughts, helping her maintain steady weight without yo-yoing.

These side effects highlight risks of rapid weight loss, including premature aging appearances in areas like the neck and feet, as noted by experts analyzing similar cases with celebrities like Sharon Osbourne. Despite this, Winfrey expressed satisfaction with the tools impact on her life.

Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

Recent studies from the past week highlight new insights into Ozempic and similar GLP-1 medications for weight loss. Researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia analyzed large-scale data and found that semaglutide, the active ingredient in Ozempic, significantly reduces risks of depression, anxiety, and addiction alongside its weight loss effects. According to their work published in The Lancet Psychiatry, users experienced a 44 percent lower risk of depression and a 38 percent drop in anxiety disorders during treatment periods. Psychiatric hospital visits fell by 42 percent, and substance use disorders decreased by 47 percent compared to times without the medication. The team suggests these benefits may stem from lifestyle changes or direct effects on the brain.

Another study from Washington University School of Medicine, reported by Fox News, warns that stopping GLP-1 drugs like Ozempic quickly erodes heart health gains. Continuous use over three years lowered cardiovascular risk by 18 percent through reductions in cholesterol, blood pressure, inflammation, and insulin resistance. However, quitting for six months raised risk by 4 percent, one year by 14 percent, and two years by 22 percent. Restarting the drugs provided partial protection, only 12 percent, indicating some lasting damage from discontinuation. Lead researcher Ziyad Al-Aly described this as metabolic whiplash, with silent reversals in metabolic health that could lead to heart attacks or strokes.

Oprah Winfrey continues to draw attention for her weight loss transformation using GLP-1 medications. The List reports that recent before-and-after photos from events like the 2025 Tony Awards reveal Ozempic neck, a sagging, crepey skin effect under the jaw due to rapid fat loss outpacing skin adjustment. Winfrey has been seen favoring high-necked outfits to camouflage the loose folds, a common side effect among users.

These developments underscore the dual-edged nature of Ozempic for weight management, offering mental and heart benefits during use but posing challenges with side effects and discontinuation.

Thanks for tuning in, listeners, please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

A new study from the Cleveland Clinic, released this week, reveals that stopping weight-loss drugs like Ozempic and Mounjaro does not always lead to the rapid weight regain seen in earlier trials. Researchers analyzed nearly eight thousand patients who discontinued these injectable medications, known as GLP-one drugs, after using them for obesity or type two diabetes. Those treated for obesity lost an average of eight point four percent of their body weight before stopping and regained just zero point five percent after one year. For diabetes patients, the average loss was four point four percent before discontinuation, followed by an additional one point three percent loss over the next year. Many participants restarted the drugs, switched to alternatives, or turned to lifestyle changes like working with dietitians, helping them maintain or even improve their results. Hamlet Gasoyan, the lead researcher, noted that real-world flexibility in treatment plans explains why outcomes differ from strict clinical trials, where regain was over half the lost weight.

However, another study from Washington University School of Medicine, also published this week, warns that halting these drugs can quickly erode heart health benefits. In tracking over three hundred thirty-three thousand veterans with type two diabetes, continuous three-year use reduced cardiovascular risks like heart attack and stroke by eighteen percent. Stopping for six months raised risk by four percent, one year by fourteen percent, and two years by twenty-two percent. Restarting offered partial protection at twelve percent reduction, but not full recovery. Researcher Ziad Al-Aly described this as metabolic whiplash, with rising cholesterol, blood pressure, and inflammation that silently builds danger.

Oprah Winfrey, who has openly discussed her use of GLP-one medications for weight loss, continues to show visible effects in recent appearances. Photos from events like Paris Fashion Week earlier this year highlight what observers call Ozempic neck, loose skin under the jaw from rapid fat loss. Winfrey has favored high-neck outfits to address it, and some recent images suggest possible skin treatments are improving the appearance. She previously shared that the drugs made her feel more alive, stressing the need to start slowly to avoid side effects.

These findings underscore the value of ongoing medical guidance for long-term success with Ozempic and similar drugs. Thanks for tuning in, listeners, please come back next week for more. Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

Recent research from Cleveland Clinic is challenging what many people thought they knew about stopping weight loss medications like Ozempic and Wegovy. A new study published in the journal Diabetes, Obesity and Metabolism analyzed nearly eight thousand patients who used semaglutide or tirzepatide for three to twelve months before discontinuing treatment. The findings offer surprising hope compared to earlier clinical trials that suggested dramatic weight regain after stopping these drugs.

In the real world, patients who stopped taking these medications regained far less weight than researchers expected. Among those treated specifically for obesity, the average weight loss before stopping was eight point four percent. One year later, they had regained just half a percent on average. The key difference between this study and previous clinical trials comes down to what happens after patients stop. In real world settings, patients have more options. According to lead researcher Dr. Hamlet Gasoyan from Cleveland Clinic, many patients who stop taking semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which explains why they regain less weight than patients in randomized trials.

The research found that about twenty seven percent of patients switched to different medications including older generation obesity drugs, while another twenty percent eventually restarted their original medication once insurance issues or side effects were resolved. Another fourteen percent moved to intensive lifestyle modification programs working with dietitians and exercise specialists. This ongoing engagement with healthcare support appears to be the crucial factor in maintaining weight loss.

The findings have resonated with high profile discussions about these medications. Media mogul Oprah Winfrey recently addressed viral speculation about her weight loss after appearing at Paris Fashion Week in early March. While some online observers speculated about her use of GLP-1 medications, Oprah clarified that her careful walk into the venue was simply because she could not see clearly without her glasses or contacts. However, Oprah previously disclosed in a December 2023 interview that she does use weight management medication and described it as feeling like relief and redemption. When she briefly stopped taking the medication less than six months after starting, she gained about twenty pounds over twelve months despite maintaining a healthy diet and exercise routine. This experience convinced her that the medication may be necessary long term, and she has stated it will likely be a lifetime commitment for her.

The Cleveland Clinic study suggests that the dramatic weight rebound seen in controlled clinical trials may not reflect what actually happens in everyday medical practice. When patients maintain connection with healthcare providers through alternative treatments or structured support, they can successfully manage their weight even after stopping their initial medication. This real world evidence provides an encouraging perspective for the millions of people currently using these popular weight loss drugs.

Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI

A recent analysis from the University of Cambridge, published in eClinicalMedicine, reveals that people stopping Ozempic-like drugs such as semaglutide and tirzepatide retain about twenty-five percent of their lost weight up to one year later. However, researchers note a key uncertainty: much of the weight loss during treatment, potentially forty to sixty percent, may come from lean muscle mass rather than fat, and it remains unclear if regained weight restores muscle proportionately. The study, reviewing six high-quality randomized controlled trials with over three thousand two hundred participants, found rapid initial regain slowing over time, with sixty percent of lost weight back after one year and projections of seventy-five percent by fifteen months. Medical researcher Brajan Budini explains that these drugs mimic glucagon-like peptide-one, curbing appetite like brakes, but stopping them leads to quick rebound unless paired with diet and exercise.

Contrasting this, a Cleveland Clinic study published in Diabetes, Obesity and Metabolism, analyzing nearly eight thousand patients, shows more optimistic real-world outcomes. Patients who discontinued semaglutide or tirzepatide regained little weight on average after one year, with obesity patients holding onto most of their eight point four percent loss and diabetes patients even shedding more. Doctor Hamlet Gasoyan attributes this to many restarting medication, switching treatments, or adopting lifestyle changes, countering clinical trial data where over half the weight returns without intervention. Cost and side effects drive most discontinuations, yet forty-five percent of obesity patients stabilized or continued losing weight.

Safety concerns persist, as the United Kingdom's Medicines and Healthcare products Regulatory Agency warned on March second that semaglutide may rarely link to nonarteritic anterior ischemic optic neuropathy, a sudden vision loss condition. Meanwhile, the Food and Drug Administration admonished Novo Nordisk on March twelfth for failing to report potential side effects timely. Ongoing lawsuits focus on gastroparesis and these eye risks, with multidistrict litigation growing amid reports of stomach paralysis from higher doses.

No fresh comments from Oprah Winfrey on Ozempic emerged this week, though her past stance rejects body shame in weight discussions.

Thanks for tuning in, listeners. Please subscribe, come back next week for more, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI